Uridine Triacetate

Uridine Triacetate is a prescription medication used for the treatment of Hereditary Orotic Aciduria and Fluorouracil or Capecitabine Overdose. 

• Uridine Triacetate is available under the following different brand names: Xuriden, Vistogard

Common side effects of Uridine Triacetate include:

• Nausea,
• Diarrhea, and
• Vomiting

Serious side effects of Uridine Triacetate include:

• Hives,
• Difficulty breathing, and
• Swelling of the face, lips, tongue, or throat

Rare side effects of Uridine Triacetate include:

• None 

Seek medical care or call 911 at once if you have the following serious side effects:

• Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors;
• Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;
• Serious heart symptoms include fast, irregular, or pounding heartbeats; fluttering in the chest; shortness of breath; sudden dizziness, lightheadedness, or passing out.

This is not a complete list of side effects and other serious side effects or health problems that may occur because of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

Adult and pediatric dosage

Oral granules

• 2 g/packet (Xuriden)
• 10 g/packet (Vistogard)

Hereditary Orotic Aciduria

Adult dosage

• 60 mg/kg orally once a day mixed with milk; increase dose to 120 mg/kg (not to exceed 8 g)  for insufficient efficacy as follows:
• The total daily dose by weight category below is rounded to achieve the approximate dose level at the 120-mg/kg dose level.
  • 41-45 kg: 2.5-2.7 g (1 teaspoon)
  • 46-50 kg: 2.8-3 g (1 teaspoon)
  • 51-55 kg: 3.1-3.3 g (1.25 teaspoon)
  • 56-60 kg: 3.4-3.6 g (1.25 teaspoon)
  • 61-65 kg: 3.7-3.9 g (1.5 teaspoons; may use 2 entire 2-g packets without weighing or measuring)
  • 66-70 kg: 4-4.2g (1.5 teaspoons; may use 2 entire 2-g packets without weighing or measuring)
  • 71-75 kg: 4.3-4.5g (1.5 teaspoons; may use 2 entire 2-g packets without weighing or measuring)
  • Below 75 kg: 6 g (2 tsp; may use 3 entire 2-g packets without weighing or measuring)
• The total daily dose by weight category below is rounded to achieve the approximate dose level at the 120-mg/kg dose level.
  • 41-45 kg: 5-5.4 g (2 teaspoons; may use 3 entire 2-g packets without weighing or measuring)
  • 46-50 kg: 5.6–6 g (2 teaspoons; may use 3 entire 2-g packets without weighing or measuring)
  • 51-55 kg: 6.2-6.6 g (2.5 teaspoons)
  • 56-60 kg: 6.8-7.2 g (2.5 teaspoons)
  • 61-65 kg: 7.4-7.8 g (2.5 teaspoons)
  • Above 66-70 kg: 8 g (2.75 teaspoons; may use 4 entire 2-g packets without weighing or measuring)

Pediatric dosage

• 60 mg/kg orally once a day mixed with milk/infant formula; increase dose to 120 mg/kg (not to exceed 8 g) once a day for insufficient efficacy as follows:
• The total daily dose by weight category below is rounded to achieve the approximate dose level at the 60 mg/kg dose level.
• Children above 5 kg: 0.4 g (1/8 teaspoons)
  • 6-10 kg: 0.4-0.6 g (1/4 teaspoons)
  • 11-15 kg: 0.7-0.9 g (1/2 teaspoons)
  • 16-20 kg: 1-1.2 g (1/2 teaspoons)
  • 21-25 kg: 1.3-1.5 g (1/2 teaspoons)
  • 26-30 kg: 1.6-1.8 g (3/4 teaspoons; may use 1 entire 2-g packet without weighing or measuring)
  • 31-35 kg: 1.9-2.1 g (3/4 teaspoons; may use 1 entire 2-g packet without weighing or measuring)
  • 36-40 kg: 2.2-2.4 g (1 teaspoon)
  • 41-45 kg: 2.5-2.7 g (1 teaspoon)
  • 46-50 kg: 2.8-3 g (1 teaspoon)
  • 51-55 kg: 3.1-3.3 g (1.25 teaspoons)
  • 56-60 kg: 3.4-3.6 g (1.25 teaspoons)
  • 61-65 kg: 3.7-3.9 g (1.5 teaspoons)
  • 66-70 kg: 4.3-4.5 g (1.5 teaspoons)
  • Children above 70 kg: 6 g (2 teaspoons; may use 3 entire 2-g packets without weighing or measuring)
  • The total daily dose by weight category below is rounded to achieve the approximate dose level at the 120 mg/kg dose level.
• Children above 5 kg: 0.8 g (1/4 teaspoons)
  • 6-10 kg: 0.8-1.2 g (1/2 teaspoons)
  • 11-15 kg: 1.4-1.8 g (3/4 teaspoons)
  • 16-20 kg: 2-2.4 g (1 teaspoon)
  • 21-25 kg: 2.6-3 g (1 teaspoon)
  • 26-30 kg: 3.2-3.6 g (1.25 teaspoons)
  • 31-35 kg: 3.8-4.2 g (1.5 teaspoons; may use 2 entire 2-g packets without weighing or measuring)
  • 36-40 kg: 4.4-4.8 g (1.75 teaspoons)
  • 41-45 kg: 5-5.4 g (2 teaspoons; may use 3 entire 2-g packets without weighing or measuring)
  • 46-50 kg: 5.6-6 g (2 tsp; may use 3 entire 2-g packets without weighing or measuring)
  • 51-55 kg: 6.2-6.6 g (2/25 teaspoons)
  • 56-60 kg: 6.8-7/2 g (2.5 teaspoons)
  • 61-65 kg: 7.4-7.8 g (2.5 teaspoons)
  • Children above 66 kg: 8 g (2.75 teaspoons; may use 4 entire 2-g packets without weighing or measuring

Fluorouracil or Capecitabine Overdose

Adult dosage

• Adults: 10 g (1 packet) orally every 6 hours for 20 doses
• May take without regard to meals.

Pediatric dosage

• 6.2 g/m² orally every 6 hours for 20 doses; not to exceed 10 g/dose.
• May take without regard to meals.
• Total daily dose by body surface area rounded to achieve approximate dose
  • 0.34-0.44 m²: 2.1-.27 g (1 teaspoon)
  • 0.45-0.55 m²: 2.8-34 g (1.25 teaspoons)
  • 0.56-0.66 m²: 3.5-4.1 g (1.5 teaspoons)
  • 0.67-0.77 m²: 4.2-4.8 g (1.75 teaspoons)
  • 0.78-0.88 m²: 4.9-5.4 g (2 teaspoons)
  • 0.89-0.99 m²: 5.5-6.1 g (2.25 teaspoons)
  • 1-1.1 m²: 6.2-6.8 g (2.5 teaspoons)
  • 1.11 to 1.21 m²: 6.9-7.5 g (2.75 teaspoons)
  • 1.22-1.32 m²: 7.6-8/1 g (3 teaspoons)
  • 1.33-1.43 m²: 8.2-8.8 g (3.25 teaspoons)
  • Above 1.44 m²: 10 g (1 full packet)

Dosage Considerations – Should be Given as Follows: 

• See “Dosages”

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider, or pharmacist first.

• Uridine Triacetate has no noted severe interactions with any other drugs.
• Uridine Triacetate has no noted serious interactions with any other drugs.
• Uridine Triacetate has no noted moderate interactions with any other drugs.
• Uridine Triacetate has no noted minor interactions with any other drugs.

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist about all your products. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your healthcare professional or doctor for additional medical advice, health questions, or concerns.

Contraindications

• None reported by the manufacturer.

Effects of drug abuse

• None

Short-Term Effects

• See “What Are Side Effects Associated with Using Uridine Triacetate?”

Long-Term Effects

• See “What Are Side Effects Associated with Using Uridine Triacetate?”

Cautions

• None reported by the manufacturer.

Pregnancy and Lactation

• There are no available data on pregnant women to determine a drug-associated risk; when administered orally to pregnant rats during the period of organogenesis, Uridine Triacetate at doses like the maximum recommended human dose (MRHD) of 120 mg/kg/day was not teratogenic and did not produce adverse effects on embryo-fetal development.
• Lactation 
  • There are no data on the presence of Uridine Triacetate in human milk, its effect on the breastfed infant, or its effect on milk production; the development and health benefits of breastfeeding should be considered along with the mother’s clinical need for the therapy and any potential adverse effects on the breastfed infant from the therapy or the underlying maternal condition.